JPH0146511B2 - - Google Patents
Info
- Publication number
- JPH0146511B2 JPH0146511B2 JP60253621A JP25362185A JPH0146511B2 JP H0146511 B2 JPH0146511 B2 JP H0146511B2 JP 60253621 A JP60253621 A JP 60253621A JP 25362185 A JP25362185 A JP 25362185A JP H0146511 B2 JPH0146511 B2 JP H0146511B2
- Authority
- JP
- Japan
- Prior art keywords
- salt
- compounds
- cyanopyridine
- diazohydroxide
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 35
- 229910052783 alkali metal Inorganic materials 0.000 claims description 6
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 5
- 150000001340 alkali metals Chemical class 0.000 claims description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 4
- 159000000007 calcium salts Chemical class 0.000 claims description 3
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 2
- RMXPLKLZDZIDEV-UHFFFAOYSA-N dihydroxyazaniumylideneazanide Chemical class O[N+](O)=[N-] RMXPLKLZDZIDEV-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 13
- 239000002552 dosage form Substances 0.000 abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 8
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 230000010261 cell growth Effects 0.000 abstract description 4
- 239000000824 cytostatic agent Substances 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 description 35
- -1 basic salt compounds Chemical class 0.000 description 18
- 235000002639 sodium chloride Nutrition 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000007787 solid Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000005342 ion exchange Methods 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001085 cytostatic effect Effects 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 159000000003 magnesium salts Chemical class 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- KDVBYUUGYXUXNL-UHFFFAOYSA-N 6-aminopyridine-3-carbonitrile Chemical compound NC1=CC=C(C#N)C=N1 KDVBYUUGYXUXNL-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000003070 absorption delaying agent Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 150000003388 sodium compounds Chemical class 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 description 1
- HRLVPHGCEGTVLK-UHFFFAOYSA-N 5-cyanopyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(C#N)C=N1 HRLVPHGCEGTVLK-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000008342 Leukemia P388 Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical class CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229940085678 polyethylene glycol 8000 Drugs 0.000 description 1
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
æè¡åé
æ¬çºæã¯ã·ã¢ãããªãžã³âïŒâãžã¢ãŸãããã
ã·ãã®å¡©åºæ§å¡©ååç©ã§ããæ°èŠãªååç©ããã
ãã®è£œæ³ããããã®ååç©ãå«æããå»è¬çµæç©
ããã³æäžåœ¢æ ã§ãããã®ååç©ã䜿çšããæ²»ç
æ³ã«é¢ãããæ¬çºæã®æ°èŠãªååç©ã¯è¬ççæ§è³ª
ãæããç¹ã«çŽ°èå¢æ®æå¶å€ããã³çŽ°èçé·ææ¢
å€ãšããŠæçšãªè¬å€ã§ããã
ã·ãã®å¡©åºæ§å¡©ååç©ã§ããæ°èŠãªååç©ããã
ãã®è£œæ³ããããã®ååç©ãå«æããå»è¬çµæç©
ããã³æäžåœ¢æ ã§ãããã®ååç©ã䜿çšããæ²»ç
æ³ã«é¢ãããæ¬çºæã®æ°èŠãªååç©ã¯è¬ççæ§è³ª
ãæããç¹ã«çŽ°èå¢æ®æå¶å€ããã³çŽ°èçé·ææ¢
å€ãšããŠæçšãªè¬å€ã§ããã
çºæã®èæ¯
ããªãžã³âïŒâãžã¢ãŸããããã·ãå¡©ååç©ã
ãªãã¡ïŒããªãžã³âïŒâãžã¢ãŸããŒãååç©ïŒã¯
äŸãã°ãã³ãã³ããã³ãããã³ãŠãªã«ããš
ïŒBuntonïŒMinchããã³WolfeïŒã«ãã€ãŠãžã€ãŒ
ãã«ã»ãªãã»ã¢ã¡ãªã«ã³ã»ã±ãã«ã«ã»ãœãµã€ãšã
ã€ãŒïŒJ.Am.Chem.Soc.ïŒïŒã1974幎ã第96å·»ã第
3267â3275é ã«èšèŒãããŠããããã«æç®äžç¥ã
ããŠããã
ãªãã¡ïŒããªãžã³âïŒâãžã¢ãŸããŒãååç©ïŒã¯
äŸãã°ãã³ãã³ããã³ãããã³ãŠãªã«ããš
ïŒBuntonïŒMinchããã³WolfeïŒã«ãã€ãŠãžã€ãŒ
ãã«ã»ãªãã»ã¢ã¡ãªã«ã³ã»ã±ãã«ã«ã»ãœãµã€ãšã
ã€ãŒïŒJ.Am.Chem.Soc.ïŒïŒã1974幎ã第96å·»ã第
3267â3275é ã«èšèŒãããŠããããã«æç®äžç¥ã
ããŠããã
çºæã®ç·æ¬
æ¬çºæã¯ãã®äžæ
æ§ã«ãããŠæ§é åŒ
ãåŒäžïŒ²ã¯ïŒâCNåºã§ãããïŒã¯ïŒåœéã®ã¢
ã«ã«ãªéå±ïŒ1aæã®éå±ïŒã奜ãŸããã¯ãããªãŠ
ã ãŸãã¯ã«ãªãŠã ã§ããããŸãã¯1/2åœéã®ã¢ã«
ã«ãªåé¡éå±ïŒ2aæã®éå±ïŒã奜ãŸããã¯ã«ã«ã·
ãŠã ãŸãã¯ãã°ãã·ãŠã ã§ããã ã§ããããããå¡©ã®åœ¢æ ã®ãæ°èŠãªã·ã¢ãããªãž
ã³âïŒâãžã¢ãŸããããã·ãååç©ã«é¢ãããã
ã®çŽç²ãªåœ¢æ ã®ååç©ã¯åºäœã§ãããå žåçã«ã¯
貯èµå®å®æ§ãæããã奜ãŸãããããªãŠã ååç©
ã«é¢ããŠãã®ç¹ã説æãããšãPH7.4ã«ãããŠæ°Ž
溶液ã調補ããå Žåããã®ååç©ã¯å®å®ã§çŽïŒæ
éã®å寿åœïŒhalfâlifeïŒãæããã®ã«å¯ŸããŠã
çžåœããæªçœ®æã®ããªãžã³âïŒâãžã¢ãŸããŒãã
ããªãŠã å¡©ã¯PH7.4ã®æ°Žæº¶æ¶²äžã§çŽïŒåéãšãã
å寿åœãæããã«ãããªãããã®ååç©ã¯ã·ã³å
ããã³ã¢ã³ãåã§ååšããããšãã§ããæ¬çºæã¯
ãããã®äž¡åããã³ãããã®æ··åç©ãäŒå³ããŠã
ãã
ã«ã«ãªéå±ïŒ1aæã®éå±ïŒã奜ãŸããã¯ãããªãŠ
ã ãŸãã¯ã«ãªãŠã ã§ããããŸãã¯1/2åœéã®ã¢ã«
ã«ãªåé¡éå±ïŒ2aæã®éå±ïŒã奜ãŸããã¯ã«ã«ã·
ãŠã ãŸãã¯ãã°ãã·ãŠã ã§ããã ã§ããããããå¡©ã®åœ¢æ ã®ãæ°èŠãªã·ã¢ãããªãž
ã³âïŒâãžã¢ãŸããããã·ãååç©ã«é¢ãããã
ã®çŽç²ãªåœ¢æ ã®ååç©ã¯åºäœã§ãããå žåçã«ã¯
貯èµå®å®æ§ãæããã奜ãŸãããããªãŠã ååç©
ã«é¢ããŠãã®ç¹ã説æãããšãPH7.4ã«ãããŠæ°Ž
溶液ã調補ããå Žåããã®ååç©ã¯å®å®ã§çŽïŒæ
éã®å寿åœïŒhalfâlifeïŒãæããã®ã«å¯ŸããŠã
çžåœããæªçœ®æã®ããªãžã³âïŒâãžã¢ãŸããŒãã
ããªãŠã å¡©ã¯PH7.4ã®æ°Žæº¶æ¶²äžã§çŽïŒåéãšãã
å寿åœãæããã«ãããªãããã®ååç©ã¯ã·ã³å
ããã³ã¢ã³ãåã§ååšããããšãã§ããæ¬çºæã¯
ãããã®äž¡åããã³ãããã®æ··åç©ãäŒå³ããŠã
ãã
ïŒâã·ã¢ãããªãžã³âïŒâãžã¢ãŸããããã·ã
ã®å¡©åºæ§å¡©ã®è£œæ³ æ¬çºæã®ãã®æ¹æ³ã®äžæ æ§ã«ãããŠãïŒâã¢ã
ãâïŒâã·ã¢ãããªãžã³ãäžæŽ»æ§æº¶åªäžã«å«ãŸã
ãå¡©åºãšåå¿ããããã®åå¿æ··åç©ããžã¢ãŸåã
å®äºãããŸã§äºç¡é žã¢ã«ãã«ã§åŠçããã€ãã§ã
ã®çæç©ãåå¿æ··åç©ããå¡©ã®åœ¢æ ã§åé¢ããã
ãšãããªããïŒâã·ã¢ãããªãžã³âïŒâãžã¢ãŸã
ãããã·ãã®ã¢ã«ã«ãªéå±å¡©ãŸãã¯ã¢ã«ã«ãªåé¡
éå±å¡©ã補é ããæ¹æ³ãå å«ããã
ã®å¡©åºæ§å¡©ã®è£œæ³ æ¬çºæã®ãã®æ¹æ³ã®äžæ æ§ã«ãããŠãïŒâã¢ã
ãâïŒâã·ã¢ãããªãžã³ãäžæŽ»æ§æº¶åªäžã«å«ãŸã
ãå¡©åºãšåå¿ããããã®åå¿æ··åç©ããžã¢ãŸåã
å®äºãããŸã§äºç¡é žã¢ã«ãã«ã§åŠçããã€ãã§ã
ã®çæç©ãåå¿æ··åç©ããå¡©ã®åœ¢æ ã§åé¢ããã
ãšãããªããïŒâã·ã¢ãããªãžã³âïŒâãžã¢ãŸã
ãããã·ãã®ã¢ã«ã«ãªéå±å¡©ãŸãã¯ã¢ã«ã«ãªåé¡
éå±å¡©ã補é ããæ¹æ³ãå å«ããã
ãã®æ¹æ³ã¯åå¿äœããã³åå¿æ¡ä»¶ã®äž¡æ¹ãšãå¯
æã倧ããå€ããããšãã§ãããã奜ãŸããã¯å®
質äžåå¿äœã®åœã¢ã«éã䜿çšãããã¢ã«ã«ãªéå±
ã¢ã«ã³ãã·ããã¢ããããã³ææ©éå±ååç©ãå«
ãããããããªå¡©åºã䜿çšããããšãã§ãããã
ããªãŠã ã¢ããã¯å¥œãŸããå¡©åºã§ãããã«ãªãŠã
ã¢ããã䜿çšããããšãã§ãããäœçŽïŒC1ãC4ïŒ
ã¢ã«ãã«ãªããŠã ãŸãã¯ãããªãŠã ååç©ã¯å¥œãŸ
ããææ©éå±å¡©åºã§ãããå€æãããéå±çæç©
ãåé¢ããç®çã§éå±ã€ãªã³ãå¥ãªéå±ã€ãªã³ã«
å€æããããã«ãäŸãã°ã¹ã«ãã³é žã«ããªã³äº€æ
æš¹èã®é©åœãªéå±å¡©ã®ã«ã©ã ãçšããã€ãªã³äº€æ
ã¯ãããã°ã©ãã€ãŒãé©å®äœ¿çšãããäºç¡é žã¢ã«
ãã«è©Šè¬ã¯äŸãã°ã¡ãã«ããšãã«ããããã«ãïœ
âããã«ããã³ïœâãã³ãã«äºç¡é žå¡©ãå«ãäºç¡
é žäœçŽã¢ã«ãã«ïŒC1ãC6ïŒããéžã¶ã®ãé©åœã§
ãããäºç¡é žã€ãœã¢ãã«ã¯é©åœãªäºç¡é žå¡©ã§ã
ãã溶åªã¯ããã©ããããã©ã³ïŒTHFïŒããšãã«
ãšãŒãã«ããžãªããµã³ããžã¡ããã·ãšã¿ã³ãŸãã¯
ä»ã®ã¢ã«ãã«ã¢ãâããžâãŸãã¯ããªãšãŒãã«æº¶
åªããéžã¶ã®ãé©åœã§ããããTHFã奜ãŸãã
溶åªã§ãããåå¿æž©åºŠã¯å³å¯ã§ã¯ãªãã10ã100
âã®ç¯å²ã®æž©åºŠãé©åœã«äœ¿çšããããšãã§ãã
ããçŽ18ãçŽ28âã®ç¯å²ã®æž©åºŠã奜ãŸãããçŽ15
ã20æéã®åå¿æéãèŠããã®ãæ®éã§ããã
æã倧ããå€ããããšãã§ãããã奜ãŸããã¯å®
質äžåå¿äœã®åœã¢ã«éã䜿çšãããã¢ã«ã«ãªéå±
ã¢ã«ã³ãã·ããã¢ããããã³ææ©éå±ååç©ãå«
ãããããããªå¡©åºã䜿çšããããšãã§ãããã
ããªãŠã ã¢ããã¯å¥œãŸããå¡©åºã§ãããã«ãªãŠã
ã¢ããã䜿çšããããšãã§ãããäœçŽïŒC1ãC4ïŒ
ã¢ã«ãã«ãªããŠã ãŸãã¯ãããªãŠã ååç©ã¯å¥œãŸ
ããææ©éå±å¡©åºã§ãããå€æãããéå±çæç©
ãåé¢ããç®çã§éå±ã€ãªã³ãå¥ãªéå±ã€ãªã³ã«
å€æããããã«ãäŸãã°ã¹ã«ãã³é žã«ããªã³äº€æ
æš¹èã®é©åœãªéå±å¡©ã®ã«ã©ã ãçšããã€ãªã³äº€æ
ã¯ãããã°ã©ãã€ãŒãé©å®äœ¿çšãããäºç¡é žã¢ã«
ãã«è©Šè¬ã¯äŸãã°ã¡ãã«ããšãã«ããããã«ãïœ
âããã«ããã³ïœâãã³ãã«äºç¡é žå¡©ãå«ãäºç¡
é žäœçŽã¢ã«ãã«ïŒC1ãC6ïŒããéžã¶ã®ãé©åœã§
ãããäºç¡é žã€ãœã¢ãã«ã¯é©åœãªäºç¡é žå¡©ã§ã
ãã溶åªã¯ããã©ããããã©ã³ïŒTHFïŒããšãã«
ãšãŒãã«ããžãªããµã³ããžã¡ããã·ãšã¿ã³ãŸãã¯
ä»ã®ã¢ã«ãã«ã¢ãâããžâãŸãã¯ããªãšãŒãã«æº¶
åªããéžã¶ã®ãé©åœã§ããããTHFã奜ãŸãã
溶åªã§ãããåå¿æž©åºŠã¯å³å¯ã§ã¯ãªãã10ã100
âã®ç¯å²ã®æž©åºŠãé©åœã«äœ¿çšããããšãã§ãã
ããçŽ18ãçŽ28âã®ç¯å²ã®æž©åºŠã奜ãŸãããçŽ15
ã20æéã®åå¿æéãèŠããã®ãæ®éã§ããã
æ¬çºæã¯ä»ã®çµæç©ã®æ
æ§ã«ãããŠã现èçé·
ææ¢éã®ïŒâã·ã¢ãããªãžã³âïŒâãžã¢ãŸããã
ãã·ãã®ã¢ã«ã«ãªéå±å¡©ãŸãã¯ã¢ã«ã«ãªåé¡éå±
å¡©ã奜ãŸããã¯ãããªãŠã å¡©ãã«ãªãŠã å¡©ãã«ã«
ã·ãŠã å¡©ãŸãã¯ãã°ãã·ãŠã å¡©ãšå»è¬çã«èš±å®¹ã
åŸãæ äœãšãå«ãã现èçé·ææ¢çšå»è¬çµæç©ã«
é¢ããã
ææ¢éã®ïŒâã·ã¢ãããªãžã³âïŒâãžã¢ãŸããã
ãã·ãã®ã¢ã«ã«ãªéå±å¡©ãŸãã¯ã¢ã«ã«ãªåé¡éå±
å¡©ã奜ãŸããã¯ãããªãŠã å¡©ãã«ãªãŠã å¡©ãã«ã«
ã·ãŠã å¡©ãŸãã¯ãã°ãã·ãŠã å¡©ãšå»è¬çã«èš±å®¹ã
åŸãæ äœãšãå«ãã现èçé·ææ¢çšå»è¬çµæç©ã«
é¢ããã
æ¬çºæã¯ãã®æ¹æ³ã®äžæ
æ§ã«ãããŠãïŒâã·ã¢
ãããªãžã³âïŒâãžã¢ãŸããããã·ãã®ã¢ã«ã«ãª
éå±å¡©ãŸãã¯ã¢ã«ã«ãªåé¡éå±å¡©ã奜ãŸããã¯ã
ã®ãããªãŠã å¡©ãã«ãªãŠã å¡©ãã«ã«ã·ãŠã å¡©ãŸã
ã¯ãã°ãã·ãŠã å¡©ã®çŽ°èçé·ææ¢éãããããå¿
èŠãšããåç©ã«æäžåœ¢æ ã§æäžããããšãããª
ããåç©ã®çŽ°èçé·ææ¢æ³ã«é¢ããã
ãããªãžã³âïŒâãžã¢ãŸããããã·ãã®ã¢ã«ã«ãª
éå±å¡©ãŸãã¯ã¢ã«ã«ãªåé¡éå±å¡©ã奜ãŸããã¯ã
ã®ãããªãŠã å¡©ãã«ãªãŠã å¡©ãã«ã«ã·ãŠã å¡©ãŸã
ã¯ãã°ãã·ãŠã å¡©ã®çŽ°èçé·ææ¢éãããããå¿
èŠãšããåç©ã«æäžåœ¢æ ã§æäžããããšãããª
ããåç©ã®çŽ°èçé·ææ¢æ³ã«é¢ããã
æ¬çºæã®ååç©ã®ç©ççããã³è¬ççæ§è³ª
æ¬çºæã®ååç©ã¯ãããã«è¿°ã¹ãããã«ãå®å®
ãªåºäœã§ãããPH7.4ãŸãã¯ãã以äžãšãããã
ãªã¢ã«ã«ãªæ§ã®PHã«ãããŠæ¯èŒçå®å®ãªæº¶æ¶²ãç
ããããã®ååç©ã¯çŽ°èå¢æ®æå¶æ§ããã³çŽ°èæ¯
æ§ïŒããªãã¡çŽ°èçé·ææ¢æ§ïŒãæãããã€æ¯å
ç©ã«ãã€ãŠäŸç€ºããããããªåç©ã«å¯Ÿããæ圢æ
ã®è¬å€ãšããŠæçšã§ããã
ãªåºäœã§ãããPH7.4ãŸãã¯ãã以äžãšãããã
ãªã¢ã«ã«ãªæ§ã®PHã«ãããŠæ¯èŒçå®å®ãªæº¶æ¶²ãç
ããããã®ååç©ã¯çŽ°èå¢æ®æå¶æ§ããã³çŽ°èæ¯
æ§ïŒããªãã¡çŽ°èçé·ææ¢æ§ïŒãæãããã€æ¯å
ç©ã«ãã€ãŠäŸç€ºããããããªåç©ã«å¯Ÿããæ圢æ
ã®è¬å€ãšããŠæçšã§ããã
æ¬çºæã®ååç©ã®æŽ»æ§ããã³ãããã®ååç©ã®
çšéã¯ãããèªäœæ £çšã«ãªã€ãŠããŠåœè©²æè¡ã§èª
ããããŠããå®éšã«ãã€ãŠç¢ºç«ãããããã®ãã
ãªè©Šéšçå®éšã®äžã€ã¯ãçäœå ã®ãªã³ãçæ§ãã
ã€ã±ãã¢ïŒleukemiaïŒP388ãè©Šéšã§ãããçšã
ãããåç©ã¯éãŸãã¯éã®CD2F1ã¯ã€ãããã¿
ã§ãè©ŠéšçŸ€åœãïŒãŸãã¯ïŒå¹ã®åç©ã䜿ãããã
现è移æ€ã¯ãªã³ãçæ§ãã€ã±ãã¢P388ã®çŽ°èã
å«ããããè ¹æ°Žæ¶²ã®è ¹èçµç¹å 泚å°ã«ãããè©Šéš
ååç©ã¯ã现èæ¥çš®ã«ã€ã¥ãããããããªæäžé
ã«ãããŠé£ç¶ïŒæ¥éã«ãããïŒæ¥ïŒåè ¹èçµç¹å
ã«æäžããããåç©ã¯ç§€éãããçãæ®ã€ãåç©
ã¯æ£èŠãªèŠæºã§30æ¥ã«ããã€ãŠèšé²ããããåŠç
åç©ïŒïŒŽïŒã®çãæ®ãæéïŒå¯Ÿç §åç©(C)ã®çãæ®
ãæéã®å²åãèšç®ããããå¹åã®åºæºã¯ïŒŽïŒïŒ£
ã®æ¯Ã100ã125ãã倧ããã125ã«çããããšã§
ããããã®è©Šéšã«ãããŠãïŒâã·ã¢ãããªãžã³â
ïŒâãžã¢ãŸããããã·ããããªãŠã å¡©ïŒããã¯æ¬
çºæã®å¡©ååç©ãšããŠã¯å žåçãªãã®ã§ããïŒã¯
äœéïŒKgåœã25mgã®æäžéã«ãããŠãæäœåºæºã
ã¯ããã«è¶ ããïŒïŒ£äŸ¡ãããªãã¡268ãšãã
ïŒïŒ£äŸ¡ãäžããã»ã©å¹åããã€ãã
çšéã¯ãããèªäœæ £çšã«ãªã€ãŠããŠåœè©²æè¡ã§èª
ããããŠããå®éšã«ãã€ãŠç¢ºç«ãããããã®ãã
ãªè©Šéšçå®éšã®äžã€ã¯ãçäœå ã®ãªã³ãçæ§ãã
ã€ã±ãã¢ïŒleukemiaïŒP388ãè©Šéšã§ãããçšã
ãããåç©ã¯éãŸãã¯éã®CD2F1ã¯ã€ãããã¿
ã§ãè©ŠéšçŸ€åœãïŒãŸãã¯ïŒå¹ã®åç©ã䜿ãããã
现è移æ€ã¯ãªã³ãçæ§ãã€ã±ãã¢P388ã®çŽ°èã
å«ããããè ¹æ°Žæ¶²ã®è ¹èçµç¹å 泚å°ã«ãããè©Šéš
ååç©ã¯ã现èæ¥çš®ã«ã€ã¥ãããããããªæäžé
ã«ãããŠé£ç¶ïŒæ¥éã«ãããïŒæ¥ïŒåè ¹èçµç¹å
ã«æäžããããåç©ã¯ç§€éãããçãæ®ã€ãåç©
ã¯æ£èŠãªèŠæºã§30æ¥ã«ããã€ãŠèšé²ããããåŠç
åç©ïŒïŒŽïŒã®çãæ®ãæéïŒå¯Ÿç §åç©(C)ã®çãæ®
ãæéã®å²åãèšç®ããããå¹åã®åºæºã¯ïŒŽïŒïŒ£
ã®æ¯Ã100ã125ãã倧ããã125ã«çããããšã§
ããããã®è©Šéšã«ãããŠãïŒâã·ã¢ãããªãžã³â
ïŒâãžã¢ãŸããããã·ããããªãŠã å¡©ïŒããã¯æ¬
çºæã®å¡©ååç©ãšããŠã¯å žåçãªãã®ã§ããïŒã¯
äœéïŒKgåœã25mgã®æäžéã«ãããŠãæäœåºæºã
ã¯ããã«è¶ ããïŒïŒ£äŸ¡ãããªãã¡268ãšãã
ïŒïŒ£äŸ¡ãäžããã»ã©å¹åããã€ãã
å»è¬çµæç©ã®èª¿è£œ
è¬å€ãŸãã¯å»è¬çµæç©ãšããŠçšããå Žåãæ¬çº
æã®ååç©ã¯ãããããªçš®é¡ã®å±æãçµå£ããã³
éçµå£æäžåœ¢æ ã«èª¿å€ãããæäžããããšããã
ã§ããã
æã®ååç©ã¯ãããããªçš®é¡ã®å±æãçµå£ããã³
éçµå£æäžåœ¢æ ã«èª¿å€ãããæäžããããšããã
ã§ããã
å»è¬çµæç©ã調å€ããã«ã¯ãåºäœãŸãã¯æ¶²äœã®
ããããã§ããåŸãäžæŽ»æ§ã®ãå»è¬çã«èš±å®¹ãåŸ
ãæ äœã䜿çšãããåºäœåœ¢æ ã®èª¿å€ã«ã¯ãç²å€ã
ã¿ãã¬ãããåæ£ãåŸãé¡ç²ãã«ãã»ã«å€ãã«ã·
ãšå€ããã³åè¬ãå«ãŸãããåºäœã®æ äœã¯åžé
å€ã調å³æã溶解å€ã最æ»å€ãæžæ¿å€ãçµåå€ãŸ
ãã¯ã¿ãã¬ãã厩å£å€ãšããŠãåãåŸãïŒçš®ãŸã
ã¯ãã以äžã®ç©è³ªã§ããããšãã§ãããããã¯ãŸ
ãã«ãã»ã«åæã§ãã€ãŠããããç²å€ã«ãããŠ
ã¯ãæ äœã¯åŸ®ç²ç ããã掻æ§ååç©ãšã®æ··åç©ã§
ãã埮ç²ç ãããåºäœã§ãããã¿ãã¬ããã«ãã
ãŠã¯ãååç©ã¯å¿ èŠãªçµåæ§ãæããæ äœãšé©åœ
ãªå²åã§æ··åãããææã®åœ¢ç¶ããã³å€§ããã«åº
ãããããç²å€ããã³ã¿ãã¬ããã¯å¥œãŸããã¯æŽ»
æ§æåã®ïŒãŸãã¯20ãªããçŽ70ïŒ ãå«ããé©åœãª
åºäœã®æ äœã¯çé žãã°ãã·ãŠã ãã¹ãã¢ãªã³é žã
ã°ãã·ãŠã ãã¿ã«ã¯ãç ç³ãã©ã¯ããŒã¹ããã¯ã
ã³ãããã¹ããªã³ãã§ãç²ããŒã©ãã³ããã©ã¬ã«
ã³ããŽã ãã¡ãã«ã»ã«ããŒã¹ãã«ã«ããã·ã¡ãã«
ã»ã«ããŒã¹ãããªãŠã ãäœèç¹ã¯ãã¯ã¹ãã³ã³ã¢
ãã¿ãŒçã§ãããã補å€ããšããçšèªã«ã¯ãæ äœ
ã«ãã€ãŠæŽ»æ§æåãïŒä»ã®æ äœãšäžç·ã«ããŸãã¯
ä»ã®æ äœç¡ãã«ïŒãããŸãã掻æ§æåãšé¢é£ããŠ
ããã«ãã»ã«ãäžããæ äœãšããŠã®ã«ãã»ã«åæ
ãšæŽ»æ§æåãšã®åŠæ³ãå«ãããšãäŒå³ãããŠã
ããåæ§ã«ã«ã·ãšå€ãå«ãŸãããã¿ãã¬ãããç²
å€ãã«ã·ãšå€ããã³ã«ãã»ã«å€ãçµå£æäžã«é©ã
ãåºäœã®æäžåœ¢æ ãšããŠäœ¿çšããããšãã§ããã
ããããã§ããåŸãäžæŽ»æ§ã®ãå»è¬çã«èš±å®¹ãåŸ
ãæ äœã䜿çšãããåºäœåœ¢æ ã®èª¿å€ã«ã¯ãç²å€ã
ã¿ãã¬ãããåæ£ãåŸãé¡ç²ãã«ãã»ã«å€ãã«ã·
ãšå€ããã³åè¬ãå«ãŸãããåºäœã®æ äœã¯åžé
å€ã調å³æã溶解å€ã最æ»å€ãæžæ¿å€ãçµåå€ãŸ
ãã¯ã¿ãã¬ãã厩å£å€ãšããŠãåãåŸãïŒçš®ãŸã
ã¯ãã以äžã®ç©è³ªã§ããããšãã§ãããããã¯ãŸ
ãã«ãã»ã«åæã§ãã€ãŠããããç²å€ã«ãããŠ
ã¯ãæ äœã¯åŸ®ç²ç ããã掻æ§ååç©ãšã®æ··åç©ã§
ãã埮ç²ç ãããåºäœã§ãããã¿ãã¬ããã«ãã
ãŠã¯ãååç©ã¯å¿ èŠãªçµåæ§ãæããæ äœãšé©åœ
ãªå²åã§æ··åãããææã®åœ¢ç¶ããã³å€§ããã«åº
ãããããç²å€ããã³ã¿ãã¬ããã¯å¥œãŸããã¯æŽ»
æ§æåã®ïŒãŸãã¯20ãªããçŽ70ïŒ ãå«ããé©åœãª
åºäœã®æ äœã¯çé žãã°ãã·ãŠã ãã¹ãã¢ãªã³é žã
ã°ãã·ãŠã ãã¿ã«ã¯ãç ç³ãã©ã¯ããŒã¹ããã¯ã
ã³ãããã¹ããªã³ãã§ãç²ããŒã©ãã³ããã©ã¬ã«
ã³ããŽã ãã¡ãã«ã»ã«ããŒã¹ãã«ã«ããã·ã¡ãã«
ã»ã«ããŒã¹ãããªãŠã ãäœèç¹ã¯ãã¯ã¹ãã³ã³ã¢
ãã¿ãŒçã§ãããã補å€ããšããçšèªã«ã¯ãæ äœ
ã«ãã€ãŠæŽ»æ§æåãïŒä»ã®æ äœãšäžç·ã«ããŸãã¯
ä»ã®æ äœç¡ãã«ïŒãããŸãã掻æ§æåãšé¢é£ããŠ
ããã«ãã»ã«ãäžããæ äœãšããŠã®ã«ãã»ã«åæ
ãšæŽ»æ§æåãšã®åŠæ³ãå«ãããšãäŒå³ãããŠã
ããåæ§ã«ã«ã·ãšå€ãå«ãŸãããã¿ãã¬ãããç²
å€ãã«ã·ãšå€ããã³ã«ãã»ã«å€ãçµå£æäžã«é©ã
ãåºäœã®æäžåœ¢æ ãšããŠäœ¿çšããããšãã§ããã
液ç¶ã®è£œå€ã«ã¯ã溶液ãæžæ¿æ¶²ããã³ä¹³æ¿æ¶²ã
å«ãŸãããäžäŸãšããŠãéçµå£æ³šå°çšã®æ°Žæº¶æ¶²ãŸ
ãã¯æ°Žâãããã¬ã³ã°ãªã³ãŒã«æº¶æ¶²ããããããš
ãã§ããã液äœè£œå€ã¯æ°Žæ§ã®ããªãšãã¬ã³ã°ãªã³
ãŒã«æº¶æ¶²äžã®æº¶æ¶²ã«åŠæ³ãããããšãã§ãããçµ
å£æäžçšã«é©åœãªæ°Žæº¶æ¶²ã¯æ°Žäžã«æŽ»æ§æåã溶解
ããé©åœãªçè²å€ã調å³æãå®å®å€ããã³ææã«
ããå¢ç²å€ãå ããããšã«ãã€ãŠã€ããããããš
ãã§ãããçµå£æäžã«é©åœãªæ°Žæ§æžæ¿æ¶²ã¯ç²æ§ç©
質ãäŸãã°å€©ç¶ãŽã ãŸãã¯åæãŽã ãæš¹èãã¡ã
ã«ã»ã«ããŒã¹ãã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ãã
ãªãŠã ããã³ä»ã®æžæ¿å€ãšãšãã«æ°Žäžã«åŸ®ç²ç ã
ãã掻æ§æåãåæ£ãããããšã«ãã€ãŠã€ããã
ãããšãã§ããã
å«ãŸãããäžäŸãšããŠãéçµå£æ³šå°çšã®æ°Žæº¶æ¶²ãŸ
ãã¯æ°Žâãããã¬ã³ã°ãªã³ãŒã«æº¶æ¶²ããããããš
ãã§ããã液äœè£œå€ã¯æ°Žæ§ã®ããªãšãã¬ã³ã°ãªã³
ãŒã«æº¶æ¶²äžã®æº¶æ¶²ã«åŠæ³ãããããšãã§ãããçµ
å£æäžçšã«é©åœãªæ°Žæº¶æ¶²ã¯æ°Žäžã«æŽ»æ§æåã溶解
ããé©åœãªçè²å€ã調å³æãå®å®å€ããã³ææã«
ããå¢ç²å€ãå ããããšã«ãã€ãŠã€ããããããš
ãã§ãããçµå£æäžã«é©åœãªæ°Žæ§æžæ¿æ¶²ã¯ç²æ§ç©
質ãäŸãã°å€©ç¶ãŽã ãŸãã¯åæãŽã ãæš¹èãã¡ã
ã«ã»ã«ããŒã¹ãã«ã«ããã·ã¡ãã«ã»ã«ããŒã¹ãã
ãªãŠã ããã³ä»ã®æžæ¿å€ãšãšãã«æ°Žäžã«åŸ®ç²ç ã
ãã掻æ§æåãåæ£ãããããšã«ãã€ãŠã€ããã
ãããšãã§ããã
å±æ補å€ã«ã¯ãã¹ãç²å€ãã¯ãªãŒã ãããŒã·ãš
ã³ãã²ã«ããã³ã¹ãã¬ãŒãå«ãŸããããããã®
çš®ã ã®å±æ補å€ã¯åšç¥ã®æ¹æ³ã§åŠæ³ãããããšã
ã§ãããäŸãã°ã¢ã¡ãªã«åè¡åœãã€ãŒã¹ãã³ãã
ã³ã·ã«ããã¢18042ïŒBastonïŒ
Pennsylvania18042ãUSAïŒã®ããã¯åºç瀟
ïŒMack Publishing Co.ïŒïŒããåºçãããã¬ã
ã³ãã³ã®å»è¬ç§åŠã®14çã43ç« ïŒRemingtonâ²s
Pharmaceutical SciencesïŒChapter43ïŒ14th
Ed.ïŒïŒãåç §ããããã
ã³ãã²ã«ããã³ã¹ãã¬ãŒãå«ãŸããããããã®
çš®ã ã®å±æ補å€ã¯åšç¥ã®æ¹æ³ã§åŠæ³ãããããšã
ã§ãããäŸãã°ã¢ã¡ãªã«åè¡åœãã€ãŒã¹ãã³ãã
ã³ã·ã«ããã¢18042ïŒBastonïŒ
Pennsylvania18042ãUSAïŒã®ããã¯åºç瀟
ïŒMack Publishing Co.ïŒïŒããåºçãããã¬ã
ã³ãã³ã®å»è¬ç§åŠã®14çã43ç« ïŒRemingtonâ²s
Pharmaceutical SciencesïŒChapter43ïŒ14th
Ed.ïŒïŒãåç §ããããã
å»è¬è£œå€ã¯åäœæäžåœ¢æ
ã§ããããšã奜ãŸã
ãããã®ãããªåœ¢æ ã§ã¯ããã®è£œå€ã¯æŽ»æ§æåã®
é©åœãªéãå«ãåäœæäžåœ¢æ ã«ååå²ããããå
äœæäžåœ¢æ ã¯å è£ ããã補å€ã§ããããšãã§ãã
補å€ã®å¥ã ãªéãå«ãå è£ ãäŸãã°å°å ã«ããã
ã¿ãã¬ãããã«ãã»ã«ããã³è¬ã³ããŸãã¯ã¢ã³ã
ã«ã«å ¥ã€ãç²æ«ã§ããããšãã§ãããåäœæäžåœ¢
æ ã¯ã«ãã»ã«ãã«ã·ãšãŸãã¯ã¿ãã¬ããããèªäœ
ã§ãã€ãŠãããããŸãã¯ä»»æã®ãã®ãããªå è£ åœ¢
æ ã®é©åœãªæ°ã§ãã€ãŠãããã
ãããã®ãããªåœ¢æ ã§ã¯ããã®è£œå€ã¯æŽ»æ§æåã®
é©åœãªéãå«ãåäœæäžåœ¢æ ã«ååå²ããããå
äœæäžåœ¢æ ã¯å è£ ããã補å€ã§ããããšãã§ãã
補å€ã®å¥ã ãªéãå«ãå è£ ãäŸãã°å°å ã«ããã
ã¿ãã¬ãããã«ãã»ã«ããã³è¬ã³ããŸãã¯ã¢ã³ã
ã«ã«å ¥ã€ãç²æ«ã§ããããšãã§ãããåäœæäžåœ¢
æ ã¯ã«ãã»ã«ãã«ã·ãšãŸãã¯ã¿ãã¬ããããèªäœ
ã§ãã€ãŠãããããŸãã¯ä»»æã®ãã®ãããªå è£ åœ¢
æ ã®é©åœãªæ°ã§ãã€ãŠãããã
補å€ã®åäœæäžã«ããã掻æ§ååç©ã®éã¯ç¹å®
ã®é©çšããã³æŽ»æ§æåã®å¹èœã«ãããã€ãŠå€ãã
ããšãã§ããæãã¯50mgãªãã500mgã«èª¿ç¯ãã
ãã
ã®é©çšããã³æŽ»æ§æåã®å¹èœã«ãããã€ãŠå€ãã
ããšãã§ããæãã¯50mgãªãã500mgã«èª¿ç¯ãã
ãã
è¬å€ãšããŠæ²»çã«çšããå Žåã«ã¯ãæ¬çºæã®æ²»
çæ³ã«å©çšãããååç©ã¯KgåœãçŽ0.1mgãªãã
çŽ50mgã®åææäžéã§æäžããããKgåœãçŽ0.5
mgãªããçŽ10mgã®æäžç¯å²ã奜ãŸãããç¹æ®äºæ
ã«å¯Ÿããé©åœãªæäžéã®æ±ºå®ã¯å»è ã®çç·Žã®ç¯å²
ã«ãããäžè¬ã«ãæ²»çã¯ãã®ååç©ã®å°ãªãæäž
éããªãã¡æé©æäžéããå°ãªãæäžéãçšããŠ
éå§ãããããããã®ã¡ã«ãã®ç°å¢ã®äžã§æé©ã®
å¹æãéãããããŸã§å°ãã¥ã€å¢ããããã䟿å®
äžãæ¯æ¥ã®å šæäžéãåããããšãã§ããææãª
ãã°ïŒæ¥ã®éã«æ°åã«åããŠæäžããããšãã§ã
ãã
çæ³ã«å©çšãããååç©ã¯KgåœãçŽ0.1mgãªãã
çŽ50mgã®åææäžéã§æäžããããKgåœãçŽ0.5
mgãªããçŽ10mgã®æäžç¯å²ã奜ãŸãããç¹æ®äºæ
ã«å¯Ÿããé©åœãªæäžéã®æ±ºå®ã¯å»è ã®çç·Žã®ç¯å²
ã«ãããäžè¬ã«ãæ²»çã¯ãã®ååç©ã®å°ãªãæäž
éããªãã¡æé©æäžéããå°ãªãæäžéãçšããŠ
éå§ãããããããã®ã¡ã«ãã®ç°å¢ã®äžã§æé©ã®
å¹æãéãããããŸã§å°ãã¥ã€å¢ããããã䟿å®
äžãæ¯æ¥ã®å šæäžéãåããããšãã§ããææãª
ãã°ïŒæ¥ã®éã«æ°åã«åããŠæäžããããšãã§ã
ãã
æ¬ååç©ã¯éçµå£çã«ãæãã¯è
¹èçµç¹å
ã«æ
äžããããšãã§ãããææãªãã°ããããã·ãã
ãã«ã»ã«ããŒã¹ã®ãããªçé¢æŽ»æ§å€ãšæ°Žäžã§æ··å
ããŠæ¬ååç©ã®æº¶æ¶²ãã€ããããšãã§ãããã°ãª
ã»ãªã³ã液ç¶ããªãšãã¬ã³ã°ãªã³ãŒã«ããã³ãã
ãã®æ··åç©äžã§ãããã³æ²¹äžã§åæ£æ¶²ãã€ããã
ãšãã§ããã貯èµããã³äœ¿çšã®æ®éã®æ¡ä»¶ã®äžã§
ã¯ãããã®è£œå€ã¯åŸ®çç©ã®æé·ãé²ãããã«é²è
å€ãå«ãã
äžããããšãã§ãããææãªãã°ããããã·ãã
ãã«ã»ã«ããŒã¹ã®ãããªçé¢æŽ»æ§å€ãšæ°Žäžã§æ··å
ããŠæ¬ååç©ã®æº¶æ¶²ãã€ããããšãã§ãããã°ãª
ã»ãªã³ã液ç¶ããªãšãã¬ã³ã°ãªã³ãŒã«ããã³ãã
ãã®æ··åç©äžã§ãããã³æ²¹äžã§åæ£æ¶²ãã€ããã
ãšãã§ããã貯èµããã³äœ¿çšã®æ®éã®æ¡ä»¶ã®äžã§
ã¯ãããã®è£œå€ã¯åŸ®çç©ã®æé·ãé²ãããã«é²è
å€ãå«ãã
泚å°çšã«é©åœãªå»è¬åœ¢æ
ã«ã¯ç¡èã®æ°Žæº¶æ¶²ãŸã
ã¯åæ£æ¶²ãå«ãŸãããŸãç¡èã®æ³šå°çšæº¶æ¶²ãŸãã¯
åæ£æ¶²ããã®å Žã§èª¿è£œããããã®ç¡èã®ç²æªãå«
ãŸãããããããå Žåã«ãã®åœ¢æ ã¯ç¡èã§ãªãã
ã°ãªããããŸã容æã«æ³šå°ã§ããçšåºŠã«æµåæ§ã§
ãªããã°ãªããªããããã¯è£œé ããã³è²¯èµã®æ¡ä»¶
ã®ããšã§å®å®ã§ãªããã°ãªããããŸããã¯ããªã€
ããã³ã®ãããªåŸ®çç©ã®æ±æäœçšã«å¯ŸããŠä¿è·ã
ããªããã°ãªããªããæ äœã¯äŸãã°æ°Žããšã¿ããŒ
ã«ãããªãªãŒã«ïŒäŸãã°ã°ãªã»ãªã³ããããã¬ã³
ã°ãªã³ãŒã«ããã³æ¶²ç¶ããªãšãã¬ã³ã°ãªã³ãŒã«ãª
ã©ïŒãïŒïŒ®âãžã¡ãã«ã¢ã»ãã¢ããããããã®
é©åœãªæ··åç©ããã³æ€ç©æ²¹ãå«ã溶åªãŸãã¯åæ£
åªäœã§ããããšãã§ãããé©åœãªæµåæ§ã¯ãäŸã
ã°ã¬ã·ãã³ã®ãããªè¢«èŠã®äœ¿çšã«ãããæãã¯å
æ£æ¶²ã®å Žåã«ã¯ææã®ç²åŸã®ä¿æã«ãããæãã¯
çé¢æŽ»æ§å€ã®äœ¿çšã«ããç¶æããããšãã§ããã
埮çç©ã®äœçšã«äºé²ã¯çš®ã ã®æèå€ããã³æçè
å€äŸãã°ãã©ãã³ãã¯ãããã¿ããŒã«ãããšããŒ
ã«ããœã«ãã³é žãã·ã¡ããµã«ãªã©ã«ãã€ãŠãªããš
ããããšãã§ãããå€ãã®å Žåãç匵å€äŸãã°ç
ç³ãŸãã¯å¡©åãããªãŠã ãå«æãããããšã奜ãŸ
ããã泚å°å¯èœãªçµæç©ã®åžåãé·åŒãããã«ã¯
çµæç©äžã«åžåé 延å€ãäŸãã°ã¢ã«ãããŠã ã¢ã
ã¹ãã¢ã¬ãŒãããã³ãŒã©ãã³ã䜿çšããããšã«ã
ã€ãŠãªããšããããšãã§ããã
ã¯åæ£æ¶²ãå«ãŸãããŸãç¡èã®æ³šå°çšæº¶æ¶²ãŸãã¯
åæ£æ¶²ããã®å Žã§èª¿è£œããããã®ç¡èã®ç²æªãå«
ãŸãããããããå Žåã«ãã®åœ¢æ ã¯ç¡èã§ãªãã
ã°ãªããããŸã容æã«æ³šå°ã§ããçšåºŠã«æµåæ§ã§
ãªããã°ãªããªããããã¯è£œé ããã³è²¯èµã®æ¡ä»¶
ã®ããšã§å®å®ã§ãªããã°ãªããããŸããã¯ããªã€
ããã³ã®ãããªåŸ®çç©ã®æ±æäœçšã«å¯ŸããŠä¿è·ã
ããªããã°ãªããªããæ äœã¯äŸãã°æ°Žããšã¿ããŒ
ã«ãããªãªãŒã«ïŒäŸãã°ã°ãªã»ãªã³ããããã¬ã³
ã°ãªã³ãŒã«ããã³æ¶²ç¶ããªãšãã¬ã³ã°ãªã³ãŒã«ãª
ã©ïŒãïŒïŒ®âãžã¡ãã«ã¢ã»ãã¢ããããããã®
é©åœãªæ··åç©ããã³æ€ç©æ²¹ãå«ã溶åªãŸãã¯åæ£
åªäœã§ããããšãã§ãããé©åœãªæµåæ§ã¯ãäŸã
ã°ã¬ã·ãã³ã®ãããªè¢«èŠã®äœ¿çšã«ãããæãã¯å
æ£æ¶²ã®å Žåã«ã¯ææã®ç²åŸã®ä¿æã«ãããæãã¯
çé¢æŽ»æ§å€ã®äœ¿çšã«ããç¶æããããšãã§ããã
埮çç©ã®äœçšã«äºé²ã¯çš®ã ã®æèå€ããã³æçè
å€äŸãã°ãã©ãã³ãã¯ãããã¿ããŒã«ãããšããŒ
ã«ããœã«ãã³é žãã·ã¡ããµã«ãªã©ã«ãã€ãŠãªããš
ããããšãã§ãããå€ãã®å Žåãç匵å€äŸãã°ç
ç³ãŸãã¯å¡©åãããªãŠã ãå«æãããããšã奜ãŸ
ããã泚å°å¯èœãªçµæç©ã®åžåãé·åŒãããã«ã¯
çµæç©äžã«åžåé 延å€ãäŸãã°ã¢ã«ãããŠã ã¢ã
ã¹ãã¢ã¬ãŒãããã³ãŒã©ãã³ã䜿çšããããšã«ã
ã€ãŠãªããšããããšãã§ããã
ç¡èã®æ³šå°å¯èœãªæº¶æ¶²ã¯é©åœãªæº¶åªäžã«æèŠé
ã®æŽ»æ§ååç©ããææã«ããäžèšã®ãããããªä»
ã®æåãšãšãã«æ··å ¥ããæ¿Ÿéã«ãã€ãŠéæããã
ç¡èåãè¡ãããšã«ãã€ãŠã€ãããããäžè¬ã«ã
åæ£æ¶²ã¯å¡©åºæ§åæ£åªäœããã³äžèšããéžãã ä»
ã®æèŠæåãå«ãç¡èã®ããã¯ã«äžã«ãããããª
ç¡èåããã掻æ§æåãæ··å ¥ããããšã«ãã€ãŠã€
ãããããç¡èã®æ³šå°å¯èœãªæº¶æ¶²ã補é ãããã
ã®ç¡èã®ç²æªã®å Žåã«ãããŠã奜ãŸãã補å€æ¹æ³
ã¯ç空也ç¥æ³ããã³åçµä¹Ÿç¥æ³ã§ããããããã«
ãã€ãŠæŽ»æ§æåã®ç²æ«ã«ãåã«ã€ãã€ãŠãããç¡
èåããæ¿Ÿé溶液ããã®è¿œå ã®æææåãå ãã€
ãç²æ«ãçãããæ¬æ现æžã§äœ¿çšãããå»è¬çã«
蚱容ãåŸãæ äœããšããçšèªã«ã¯ãä»»æã®ããã
ã³ãã¹ãŠã®æº¶åªãåæ£åªäœã被èãæèå€ããã³
æçèå€ãç匵å€ããã³åžåé 延å€ãªã©ãå«ãŸã
ããå»è¬çã«æŽ»æ§ãªç©è³ªã«å¯ŸããŠãã®ãããªåªäœ
ãŸãã¯å€ã䜿çšããããšã¯åœè©²æè¡ã«ãããŠãã
ç¥ãããŠãããä»»æã®ãæ £çšã®åªäœãŸãã¯å€ã掻
æ§æåãšçžå®¹ããªãå Žåãã®ãããæ²»ççšçµæç©
äžã®ãã®äœ¿çšãæå³ããããè£å©çãªæŽ»æ§æåã
çµæç©äžã«æ··å ¥ããããšãã§ããã
ã®æŽ»æ§ååç©ããææã«ããäžèšã®ãããããªä»
ã®æåãšãšãã«æ··å ¥ããæ¿Ÿéã«ãã€ãŠéæããã
ç¡èåãè¡ãããšã«ãã€ãŠã€ãããããäžè¬ã«ã
åæ£æ¶²ã¯å¡©åºæ§åæ£åªäœããã³äžèšããéžãã ä»
ã®æèŠæåãå«ãç¡èã®ããã¯ã«äžã«ãããããª
ç¡èåããã掻æ§æåãæ··å ¥ããããšã«ãã€ãŠã€
ãããããç¡èã®æ³šå°å¯èœãªæº¶æ¶²ã補é ãããã
ã®ç¡èã®ç²æªã®å Žåã«ãããŠã奜ãŸãã補å€æ¹æ³
ã¯ç空也ç¥æ³ããã³åçµä¹Ÿç¥æ³ã§ããããããã«
ãã€ãŠæŽ»æ§æåã®ç²æ«ã«ãåã«ã€ãã€ãŠãããç¡
èåããæ¿Ÿé溶液ããã®è¿œå ã®æææåãå ãã€
ãç²æ«ãçãããæ¬æ现æžã§äœ¿çšãããå»è¬çã«
蚱容ãåŸãæ äœããšããçšèªã«ã¯ãä»»æã®ããã
ã³ãã¹ãŠã®æº¶åªãåæ£åªäœã被èãæèå€ããã³
æçèå€ãç匵å€ããã³åžåé 延å€ãªã©ãå«ãŸã
ããå»è¬çã«æŽ»æ§ãªç©è³ªã«å¯ŸããŠãã®ãããªåªäœ
ãŸãã¯å€ã䜿çšããããšã¯åœè©²æè¡ã«ãããŠãã
ç¥ãããŠãããä»»æã®ãæ £çšã®åªäœãŸãã¯å€ã掻
æ§æåãšçžå®¹ããªãå Žåãã®ãããæ²»ççšçµæç©
äžã®ãã®äœ¿çšãæå³ããããè£å©çãªæŽ»æ§æåã
çµæç©äžã«æ··å ¥ããããšãã§ããã
äž»ãã掻æ§æåã¯ãå¹æçãªéã䟿å©ã«ãã€å¹
æçã«æäžããããã«ãããã«èšèŒãããããªå
äœæäžåœ¢æ ã«ãããŠãå»è¬çã«èš±å®¹ãåŸãé©åœãª
æ äœãšãšãã«é åããããåäœæäžåœ¢æ ã¯ãäŸã
ã°ãçŽ0.1ãªããçŽ500mgã奜ãŸããã¯çŽ0.5ãªã
ãçŽ250mgã®ç¯å²ã®éã®äž»ãã掻æ§ååç©ãå«ãã
å²åã§ãããããšããã®ååç©ã¯äžè¬ã«çŽ0.1ãª
ããçŽ500mgïŒæ äœmlã§ãããè£å©çãªæŽ»æ§æå
ãå«ãçµæç©ã®å Žåã«ã¯ããã®çšéã¯ãã®æåã®
éåžžã®æäžéããã³æäžæ¹æ³ãåèã«ããŠæ±ºå®ã
ãããæ¯æ¥ã®éçµå£æäžéã¯0.1mgïŒKgãªãã10
mgïŒKgã®ç¯å²ã§ããã奜ãŸããæ¯æ¥ã®æäžéã¯
0.3mgïŒKgãªãã10mgïŒKgã®ç¯å²ã§ããã
æçã«æäžããããã«ãããã«èšèŒãããããªå
äœæäžåœ¢æ ã«ãããŠãå»è¬çã«èš±å®¹ãåŸãé©åœãª
æ äœãšãšãã«é åããããåäœæäžåœ¢æ ã¯ãäŸã
ã°ãçŽ0.1ãªããçŽ500mgã奜ãŸããã¯çŽ0.5ãªã
ãçŽ250mgã®ç¯å²ã®éã®äž»ãã掻æ§ååç©ãå«ãã
å²åã§ãããããšããã®ååç©ã¯äžè¬ã«çŽ0.1ãª
ããçŽ500mgïŒæ äœmlã§ãããè£å©çãªæŽ»æ§æå
ãå«ãçµæç©ã®å Žåã«ã¯ããã®çšéã¯ãã®æåã®
éåžžã®æäžéããã³æäžæ¹æ³ãåèã«ããŠæ±ºå®ã
ãããæ¯æ¥ã®éçµå£æäžéã¯0.1mgïŒKgãªãã10
mgïŒKgã®ç¯å²ã§ããã奜ãŸããæ¯æ¥ã®æäžéã¯
0.3mgïŒKgãªãã10mgïŒKgã®ç¯å²ã§ããã
æ¬çºæããã³æ¬çºæã®æè¯ã®å®æœæ
æ§ãã€ãã®
å®æœäŸã«ãã€ãŠèª¬æããã
å®æœäŸã«ãã€ãŠèª¬æããã
å®æœäŸ ïŒ
ïŒâã·ã¢ãããªãžã³âïŒâãžã¢ãŸããããã·ã
ãããªãŠã å¡© P.Z.ã°ã¬ãŽãªãŒãS.J.ãã«ãããã³R.ã¹ã©ãã¯
ïŒP.Z.GregoryïŒS.J.Holtããã³R.SlackïŒã«ãã
ãžã€ãŒãã«ã»ãªãã»ã±ãã«ã«ã»ãœãµã€ãšãã€ãŒ
ïŒJ.Chem.Soc.ïŒã1947ã87ã«èšèŒã®æ¹æ³ã«ããã
ã€ãŠã€ããããïŒâã·ã¢ãâïŒâã¢ããããªãžã³
ã®1.6ïœïŒ0.0134ã¢ã«ïŒã也ç¥ããã©ããããã©
ã³ïŒTHFïŒ50mläžãããªãŠã ã¢ãã0.52ïœ
ïŒ0.0134ã¢ã«ïŒã®æžæ¿æ¶²ã«å ãã也ç¥çªçŽ ã®ããš
ã§30åéã«ãããçããæ¹æãããšæ·¡é»è²ã®æ··å
ç©ãçããããã®æžæ¿æ¶²ã«THF5mläžäºç¡é žã€ãœ
ã¢ãã«1.79mlïŒ0.0134ã¢ã«ïŒãå ããåŸãããé»
è²æ··åç©ãçŽ23âã«ãããŠ12æéæ¹æããæ¿Ÿé
ããé»è²åºäœã§ããäž»é¡ã®çæç©ãéãã¡ã¿ããŒ
ã«ïŒãšãŒãã«ããåçµæ¶ãããåçã¯1.60ïœ
ïŒ61.4ïŒ ïŒã§ããã
ãããªãŠã å¡© P.Z.ã°ã¬ãŽãªãŒãS.J.ãã«ãããã³R.ã¹ã©ãã¯
ïŒP.Z.GregoryïŒS.J.Holtããã³R.SlackïŒã«ãã
ãžã€ãŒãã«ã»ãªãã»ã±ãã«ã«ã»ãœãµã€ãšãã€ãŒ
ïŒJ.Chem.Soc.ïŒã1947ã87ã«èšèŒã®æ¹æ³ã«ããã
ã€ãŠã€ããããïŒâã·ã¢ãâïŒâã¢ããããªãžã³
ã®1.6ïœïŒ0.0134ã¢ã«ïŒã也ç¥ããã©ããããã©
ã³ïŒTHFïŒ50mläžãããªãŠã ã¢ãã0.52ïœ
ïŒ0.0134ã¢ã«ïŒã®æžæ¿æ¶²ã«å ãã也ç¥çªçŽ ã®ããš
ã§30åéã«ãããçããæ¹æãããšæ·¡é»è²ã®æ··å
ç©ãçããããã®æžæ¿æ¶²ã«THF5mläžäºç¡é žã€ãœ
ã¢ãã«1.79mlïŒ0.0134ã¢ã«ïŒãå ããåŸãããé»
è²æ··åç©ãçŽ23âã«ãããŠ12æéæ¹æããæ¿Ÿé
ããé»è²åºäœã§ããäž»é¡ã®çæç©ãéãã¡ã¿ããŒ
ã«ïŒãšãŒãã«ããåçµæ¶ãããåçã¯1.60ïœ
ïŒ61.4ïŒ ïŒã§ããã
1H NMRïŒDMSOd6ïŒïŒ
ÎŽ7.54ïŒïœïŒ1HïŒïŒšâïŒïŒïŒªïŒ8.8HzïŒïŒ7.86ïŒïœïŒ
1HïŒïŒšâïŒïŒïŒ8.63ïŒïœïŒ1HïŒïŒšâïŒïŒïŒªïŒ2.0
HzïŒïŒ ããªãã«ãªãé ¢é žïŒTFAïŒã®ïŒæ»Žã®æ·»å ã«ã
ãïŒ ÎŽ6.43ïŒïœïŒ1HïŒïŒšâïŒïŒïŒªïŒ9.6HzïŒïŒ7.70ïŒïœïŒ
1HïŒïŒšâïŒïŒïŒ8.20ïŒïœïŒ1HïŒïŒšâïŒïŒïŒªïŒ2.4
HzïŒïŒ IRïŒKBrïŒïŒ 3400cm-1ïŒ2230cm-1ïŒïŒ£â¡ïŒ®ïŒ 1595ïŒ1470ïŒ1340ïŒ1240cm-1ã«ãããŠåŒ·ãããŒ
㯠èšç®å€ïŒNa13.51ïŒ å®æž¬å€ïŒ 14.92ïŒ å®æœäŸ ïŒ ïŒâã·ã¢ãããªãžã³âïŒâãžã¢ãŸããããã·ã
ãããªãŠã å¡© ïŒâã·ã¢ãâïŒâã¢ããããªãžã³ã®3.57ïœ
ïŒ0.03ã¢ã«ïŒãã也ç¥çªçŽ ã®ããšã§ã也ç¥THF60
mläžãããªãŠã ã¢ãã1.07ïœïŒ0.03ã¢ã«ïŒã®æžæ¿
液ã«å ãããåŸãããçœè²æ··åç©ãããã«å®€æž©ã«
ãããŠ30åéæ¹æããã€ãã§äºç¡é žã€ãœã¢ãã«ã®
4.02mlïŒ0.03ã¢ã«ïŒã滎å ããããã®æ··åç©ã¯
åŸã ã«é®®é»è²ã«å€ããæ¹æãããã«15æéç¶ã
ããçæããé»è²åºäœã®äž»é¡ã®çæç©ãæ¿Ÿéã«ã
ã€ãŠéãã20mlã®THFã§ïŒåã30mlã®ä¹Ÿç¥ãšãŒ
ãã«ã§ïŒåæŽæµããæåã¯ã¡ã¿ããŒã«ïŒãšãŒãã«
ããã®åçµæ¶ã«ãããã€ã¥ããŠã¢ã³ããŒã©ã€ã
ïŒAmberliteïŒIRâ120ïŒã¹ã«ãã³é žã®ãããªãŠã
å¡©ïŒæš¹èã®å ¥ã€ãã€ãªã³äº€æå¡ãéãããšã«ãã
粟補ãããåçã¯2.5ïœïŒ49ïŒ ïŒã§ããã
1HïŒïŒšâïŒïŒïŒ8.63ïŒïœïŒ1HïŒïŒšâïŒïŒïŒªïŒ2.0
HzïŒïŒ ããªãã«ãªãé ¢é žïŒTFAïŒã®ïŒæ»Žã®æ·»å ã«ã
ãïŒ ÎŽ6.43ïŒïœïŒ1HïŒïŒšâïŒïŒïŒªïŒ9.6HzïŒïŒ7.70ïŒïœïŒ
1HïŒïŒšâïŒïŒïŒ8.20ïŒïœïŒ1HïŒïŒšâïŒïŒïŒªïŒ2.4
HzïŒïŒ IRïŒKBrïŒïŒ 3400cm-1ïŒ2230cm-1ïŒïŒ£â¡ïŒ®ïŒ 1595ïŒ1470ïŒ1340ïŒ1240cm-1ã«ãããŠåŒ·ãããŒ
㯠èšç®å€ïŒNa13.51ïŒ å®æž¬å€ïŒ 14.92ïŒ å®æœäŸ ïŒ ïŒâã·ã¢ãããªãžã³âïŒâãžã¢ãŸããããã·ã
ãããªãŠã å¡© ïŒâã·ã¢ãâïŒâã¢ããããªãžã³ã®3.57ïœ
ïŒ0.03ã¢ã«ïŒãã也ç¥çªçŽ ã®ããšã§ã也ç¥THF60
mläžãããªãŠã ã¢ãã1.07ïœïŒ0.03ã¢ã«ïŒã®æžæ¿
液ã«å ãããåŸãããçœè²æ··åç©ãããã«å®€æž©ã«
ãããŠ30åéæ¹æããã€ãã§äºç¡é žã€ãœã¢ãã«ã®
4.02mlïŒ0.03ã¢ã«ïŒã滎å ããããã®æ··åç©ã¯
åŸã ã«é®®é»è²ã«å€ããæ¹æãããã«15æéç¶ã
ããçæããé»è²åºäœã®äž»é¡ã®çæç©ãæ¿Ÿéã«ã
ã€ãŠéãã20mlã®THFã§ïŒåã30mlã®ä¹Ÿç¥ãšãŒ
ãã«ã§ïŒåæŽæµããæåã¯ã¡ã¿ããŒã«ïŒãšãŒãã«
ããã®åçµæ¶ã«ãããã€ã¥ããŠã¢ã³ããŒã©ã€ã
ïŒAmberliteïŒIRâ120ïŒã¹ã«ãã³é žã®ãããªãŠã
å¡©ïŒæš¹èã®å ¥ã€ãã€ãªã³äº€æå¡ãéãããšã«ãã
粟補ãããåçã¯2.5ïœïŒ49ïŒ ïŒã§ããã
1H NMRïŒDMSOd6ïŒïŒ
ÎŽ7.59ïŒïœïŒ1HïŒïŒšâïŒïŒïŒªïŒ8.7HzïŒïŒ7.86ïŒddïŒ
1HïŒïŒšâïŒïŒïŒªïŒ8.7ïŒ2.1HzïŒïŒ8.62ïŒïœïŒ1HïŒ
âïŒïŒïŒªïŒ2.1HzïŒ IRïŒKBrïŒïŒ 3400cm-1ïŒ2230cm1ïŒïŒ£â¡ïŒ®ïŒ 1595ïŒ1260cm-1ã«ãããŠåŒ·ãããŒã¯ å®æœäŸ 2a ïŒâã·ã¢ãããªãžã³âïŒâãžã¢ãŸããããã·ã
ã«ãªãŠã å¡© ã€ãªã³äº€æãã«ãªãŠã 塩圢æ ã«ããæš¹èã䜿çš
ããŠè¡ãããšãã®ããå®æœäŸïŒãšåã塩圢ææ³ã«
ãã€ãŠäž»é¡ã®çæç©ãã€ããã
1HïŒïŒšâïŒïŒïŒªïŒ8.7ïŒ2.1HzïŒïŒ8.62ïŒïœïŒ1HïŒ
âïŒïŒïŒªïŒ2.1HzïŒ IRïŒKBrïŒïŒ 3400cm-1ïŒ2230cm1ïŒïŒ£â¡ïŒ®ïŒ 1595ïŒ1260cm-1ã«ãããŠåŒ·ãããŒã¯ å®æœäŸ 2a ïŒâã·ã¢ãããªãžã³âïŒâãžã¢ãŸããããã·ã
ã«ãªãŠã å¡© ã€ãªã³äº€æãã«ãªãŠã 塩圢æ ã«ããæš¹èã䜿çš
ããŠè¡ãããšãã®ããå®æœäŸïŒãšåã塩圢ææ³ã«
ãã€ãŠäž»é¡ã®çæç©ãã€ããã
å®æœäŸ 2b
ïŒâã·ã¢ãããªãžã³âïŒâãžã¢ãŸããããã·ã
ã«ã«ã·ãŠã å¡© ã€ãªã³äº€æãã«ã«ã·ãŠã 塩圢æ ã«ããæš¹èã䜿
çšããŠè¡ãããšãã®ããå®æœäŸïŒãšåã塩圢ææ³
ã«ãã€ãŠäž»é¡ã®çæç©ãã€ããã
ã«ã«ã·ãŠã å¡© ã€ãªã³äº€æãã«ã«ã·ãŠã 塩圢æ ã«ããæš¹èã䜿
çšããŠè¡ãããšãã®ããå®æœäŸïŒãšåã塩圢ææ³
ã«ãã€ãŠäž»é¡ã®çæç©ãã€ããã
å®æœäŸ 2c
ïŒâã·ã¢ãããªãžã³âïŒâãžã¢ãŸããããã·ã
ãã°ãã·ãŠã å¡© ã€ãªã³äº€æããã°ãã·ãŠã 塩圢æ ã«ããæš¹èã
䜿çšããŠè¡ãããšãã®ããå®æœäŸïŒãšåã塩圢æ
æ³ã«ãã€ãŠäž»é¡ã®çæç©ãã€ããã
ãã°ãã·ãŠã å¡© ã€ãªã³äº€æããã°ãã·ãŠã 塩圢æ ã«ããæš¹èã
䜿çšããŠè¡ãããšãã®ããå®æœäŸïŒãšåã塩圢æ
æ³ã«ãã€ãŠäž»é¡ã®çæç©ãã€ããã
å»è¬çµæç©
ã€ãã®ä»£è¡šçãªå®æœäŸïŒãªããïŒã¯ãç°ãªãæ
äœã䜿çšããå®äŸçãªå»è¬çµæç©ãšããŠãããã
ãŠããããããã®å®æœäŸäžãå®æœäŸïŒã¯éè泚å°
çšãšããŠé©åœãªæ³šå°ãåŸã圢æ ã«æ¬çºæã®ååç©
ã䜿çšããããšãäŸç€ºãããå®æœäŸïŒã¯çµå£çšã·
ã©ãã補å€ããå®æœäŸïŒã¯çµå£çšã«ãã»ã«è£œå€
ãããããŠå®æœäŸïŒã¯çµå£çšã¿ãã¬ãããèšèŒã
ããå®æœäŸïŒã¯é©åœãªåè¬ã«æ¬çºæã®ååç©ã䜿
çšããããšã«åããããŠãããå®æœäŸïŒãªããïŒ
ã«å¯ŸããŠã¯ãæåã¯çµæç©ãã€ããæ¹æ³ã«ãã€ãŠ
åèšãããŠããã
äœã䜿çšããå®äŸçãªå»è¬çµæç©ãšããŠãããã
ãŠããããããã®å®æœäŸäžãå®æœäŸïŒã¯éè泚å°
çšãšããŠé©åœãªæ³šå°ãåŸã圢æ ã«æ¬çºæã®ååç©
ã䜿çšããããšãäŸç€ºãããå®æœäŸïŒã¯çµå£çšã·
ã©ãã補å€ããå®æœäŸïŒã¯çµå£çšã«ãã»ã«è£œå€
ãããããŠå®æœäŸïŒã¯çµå£çšã¿ãã¬ãããèšèŒã
ããå®æœäŸïŒã¯é©åœãªåè¬ã«æ¬çºæã®ååç©ã䜿
çšããããšã«åããããŠãããå®æœäŸïŒãªããïŒ
ã«å¯ŸããŠã¯ãæåã¯çµæç©ãã€ããæ¹æ³ã«ãã€ãŠ
åèšãããŠããã
å®æœäŸ ïŒ
泚å°å¯èœç©è³ª
ïŒâã·ã¢ãããªãžã³âïŒâãžã¢ãŸããããã·ã
ãããªãŠã å¡© 125mgâ500mg ç±³åœè¬å±æ³æ³šå°çšæ°Žé©é å¡©ååç©ãæ°Žã«æº¶è§£ãã0.22ãã¯ãã³ã®ãã€ã«
ã¿ãŒãéããæ¿Ÿéãã溶液ãã¢ã³ãã«ãŸãã¯è¬ã³
ãã«å ããå¯å°ãããããŠç¡èåããã
ãããªãŠã å¡© 125mgâ500mg ç±³åœè¬å±æ³æ³šå°çšæ°Žé©é å¡©ååç©ãæ°Žã«æº¶è§£ãã0.22ãã¯ãã³ã®ãã€ã«
ã¿ãŒãéããæ¿Ÿéãã溶液ãã¢ã³ãã«ãŸãã¯è¬ã³
ãã«å ããå¯å°ãããããŠç¡èåããã
å®æœäŸ ïŒ
ã·ã©ãã
掻æ§æå250mgïŒã·ã©ããïŒml
ïŒâã·ã¢ãããªãžã³âïŒâãžã¢ãŸããããã·ã
ã«ãªãŠã å¡© 25ïœ ç±³åœè¬å±æ³çŽæ°Ž 200ml ããšãªãŒã·ã©ããé©éãŸã㯠1000ml å¡©ååç©ãæ°Žã«æº¶è§£ãããã ããã«æ¹æããªã
ããã®æº¶æ¶²ã«ã·ã©ãããå ããã
ã«ãªãŠã å¡© 25ïœ ç±³åœè¬å±æ³çŽæ°Ž 200ml ããšãªãŒã·ã©ããé©éãŸã㯠1000ml å¡©ååç©ãæ°Žã«æº¶è§£ãããã ããã«æ¹æããªã
ããã®æº¶æ¶²ã«ã·ã©ãããå ããã
å®æœäŸ ïŒ
ã«ãã»ã«
50mgïŒ125mgãŸãã¯500mg
ïŒâã·ã¢ãããªãžã³âïŒâãžã¢ãŸããããã·ã
ã«ã«ã·ãŠã å¡© 500ïœ ç±³åœè¬å±æ³ç¡æ°Žã©ã¯ããŒã¹é©éãŸã㯠200ïœ ã¹ããããã¯ã¹ç²æ«HM ïŒïœ è£åæ£ã®ã€ããåèŽãã¬ã³ããŒïŒtwin shell
blenderïŒäžã§å¡©ãšã©ã¯ããŒã¹ãæ··ãåãããã
ïŒåé翻転ãã¬ã³ãïŒtumble blendïŒããã®ã¡ã
è£åæ£ã§ïŒåéãã¬ã³ãããã€ãã§åã³ïŒåéç¿»
転ãã¬ã³ãããããã®ãã¬ã³ãã®äžéšãã€ãã«ã¹
ããããã¯ã¹ç²æ«ãšæ··åããïŒ30ã¹ã¯ãªãŒã³ãé
ããããããã¬ã³ãã®æ®éšã«å ããŠãã©ãããã®
æ··åãããæåãã€ãã«ïŒåéãã¬ã³ãããè£å
æ£ã§30ç§ãã¬ã³ãããããã«äœåéãã«ããã€ãŠ
翻転ãã¬ã³ãããã50mgã125mgããã³500mgå«æ
ã«ãã»ã«ãšãããããé©åœãªå€§ããã®ã«ãã»ã«ã
ãã¬ã³ãã®141mgã352.5mgãŸãã¯1410mgã§ããã
ãå å¡«ããã
ã«ã«ã·ãŠã å¡© 500ïœ ç±³åœè¬å±æ³ç¡æ°Žã©ã¯ããŒã¹é©éãŸã㯠200ïœ ã¹ããããã¯ã¹ç²æ«HM ïŒïœ è£åæ£ã®ã€ããåèŽãã¬ã³ããŒïŒtwin shell
blenderïŒäžã§å¡©ãšã©ã¯ããŒã¹ãæ··ãåãããã
ïŒåé翻転ãã¬ã³ãïŒtumble blendïŒããã®ã¡ã
è£åæ£ã§ïŒåéãã¬ã³ãããã€ãã§åã³ïŒåéç¿»
転ãã¬ã³ãããããã®ãã¬ã³ãã®äžéšãã€ãã«ã¹
ããããã¯ã¹ç²æ«ãšæ··åããïŒ30ã¹ã¯ãªãŒã³ãé
ããããããã¬ã³ãã®æ®éšã«å ããŠãã©ãããã®
æ··åãããæåãã€ãã«ïŒåéãã¬ã³ãããè£å
æ£ã§30ç§ãã¬ã³ãããããã«äœåéãã«ããã€ãŠ
翻転ãã¬ã³ãããã50mgã125mgããã³500mgå«æ
ã«ãã»ã«ãšãããããé©åœãªå€§ããã®ã«ãã»ã«ã
ãã¬ã³ãã®141mgã352.5mgãŸãã¯1410mgã§ããã
ãå å¡«ããã
å®æœäŸ ïŒ
ã¿ãã¬ãã
50mgã100mgãŸãã¯250mg
ïŒâã·ã¢ãããªãžã³âïŒâãžã¢ãŸããããã·ã
ãã°ãã·ãŠã å¡© 250ïœ ãšãããããã§ãç²NF 200.0ïœ åŸ®æ¶è³ªã»ã«ããŒã¹ 46.0ïœ ã¹ããããã¯ã¹ç²æ«HM 4.0ïœ çŽæ°Žé©éãŸã㯠300.0ml ãã©ãã¿ãªãŒãããµãŒäžã§ãšãããããã§ã
ç²ãã»ã«ããŒã¹ããã³å¡©ååç©ãäžç·ã«ïŒåéæ··
ãåãããããã®æ··ãåãããç©ã«æ°Žãå ããïŒ
åéæ··åãããåŸãããæ··åç©ãç¿ã®äžã«æ¡ãã
æ°Žåã®éãïŒãªããïŒïŒ ã«éãããŸã§ä¹Ÿç¥ããã
也ç¥ããæ··åç©ãã€ãã«äžçšåºŠã®éãã§ïŒRH2B
ã¹ã¯ãªãŒã³ãéããã€ãããã«ïŒFitzmillïŒã§ç²
ç ããããã®æ··åç©ã®äžéšã«ã¹ããããã¯ã¹ç²æ«
ãå ããïŒ30ã¹ã¯ãªãŒã³ãéãããããç²ç ãã
ãæ··åç©ã«å ããŠãã©ãããã®å šäœããã©ã ããŒ
ãªã³ã°ïŒdrum rollingïŒã«ãã€ãŠïŒåéãã¬ã³
ãããã50mgïŒ125mgãŸãã¯250mgãå«ãã¿ãã¬ã
ããã€ããã®ã«é©åœãã倧ããã®ãã³ãã䜿çšã
ãŠãäžèšã®å šäœã®æ··åç©ã®å§æŸãããã¿ãã¬ãã
ãã€ããã
ãã°ãã·ãŠã å¡© 250ïœ ãšãããããã§ãç²NF 200.0ïœ åŸ®æ¶è³ªã»ã«ããŒã¹ 46.0ïœ ã¹ããããã¯ã¹ç²æ«HM 4.0ïœ çŽæ°Žé©éãŸã㯠300.0ml ãã©ãã¿ãªãŒãããµãŒäžã§ãšãããããã§ã
ç²ãã»ã«ããŒã¹ããã³å¡©ååç©ãäžç·ã«ïŒåéæ··
ãåãããããã®æ··ãåãããç©ã«æ°Žãå ããïŒ
åéæ··åãããåŸãããæ··åç©ãç¿ã®äžã«æ¡ãã
æ°Žåã®éãïŒãªããïŒïŒ ã«éãããŸã§ä¹Ÿç¥ããã
也ç¥ããæ··åç©ãã€ãã«äžçšåºŠã®éãã§ïŒRH2B
ã¹ã¯ãªãŒã³ãéããã€ãããã«ïŒFitzmillïŒã§ç²
ç ããããã®æ··åç©ã®äžéšã«ã¹ããããã¯ã¹ç²æ«
ãå ããïŒ30ã¹ã¯ãªãŒã³ãéãããããç²ç ãã
ãæ··åç©ã«å ããŠãã©ãããã®å šäœããã©ã ããŒ
ãªã³ã°ïŒdrum rollingïŒã«ãã€ãŠïŒåéãã¬ã³
ãããã50mgïŒ125mgãŸãã¯250mgãå«ãã¿ãã¬ã
ããã€ããã®ã«é©åœãã倧ããã®ãã³ãã䜿çšã
ãŠãäžèšã®å šäœã®æ··åç©ã®å§æŸãããã¿ãã¬ãã
ãã€ããã
å®æœäŸ ïŒ
å è¬
125mgïŒ250mgãŸãã¯500mgïŒïŒïœ
ïŒâã·ã¢ãããªãžã³âïŒâãžã¢
ãŸããããã·ããããªãŠã å¡©
125mg 250mg 500mg 1540ããªãšãã¬ã³ã°ãªã³ãŒã«
1925mg 1750mg 1400mg 8000ããªãšãã¬ã³ã°ãªã³ãŒã«
825mg 750mg 600mg 60âã«ãããŠããªãšãã¬ã³ã°ãªã³ãŒã«1540ãã
ã³ããªãšãã¬ã³ã°ãªã³ãŒã«8000ãäžç·ã«è解ãã
ãã®è解ç©äžã«å¡©ååç©ã溶解ããããã®å šäœã
25âã«ãããŠåã«å ¥ããŠé©åœãªåè¬ãšããã
125mg 250mg 500mg 1540ããªãšãã¬ã³ã°ãªã³ãŒã«
1925mg 1750mg 1400mg 8000ããªãšãã¬ã³ã°ãªã³ãŒã«
825mg 750mg 600mg 60âã«ãããŠããªãšãã¬ã³ã°ãªã³ãŒã«1540ãã
ã³ããªãšãã¬ã³ã°ãªã³ãŒã«8000ãäžç·ã«è解ãã
ãã®è解ç©äžã«å¡©ååç©ã溶解ããããã®å šäœã
25âã«ãããŠåã«å ¥ããŠé©åœãªåè¬ãšããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ äžè¬åŒ ïŒåŒäžïŒ²ã¯ïŒâCNåºã§ãããïŒã¯ïŒåœéã®ã¢
ã«ã«ãªéå±ãŸãã¯1/2åœéã®ã¢ã«ã«ãªåé¡éå±ã§
ããïŒã§ããããããïŒâã·ã¢ãããªãžã³âïŒâ
ãžã¢ãŸããããã·ãã®å¡©ã ïŒ ïŒâã·ã¢ãããªãžã³âïŒâãžã¢ãŸããããã·
ããããªãŠã å¡©ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒ
ã®ååç©ã ïŒ ïŒâã·ã¢ãããªãžã³âïŒâãžã¢ãŸããããã·
ãã«ãªãŠã å¡©ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®
ååç©ã ïŒ ïŒâã·ã¢ãããªãžã³âïŒâãžã¢ãŸããããã·
ãã«ã«ã·ãŠã å¡©ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒ
ã®ååç©ã ïŒ ïŒâã·ã¢ãããªãžã³âïŒâãžã¢ãŸããããã·
ããã°ãã·ãŠã å¡©ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èš
èŒã®ååç©ã
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US670203 | 1984-11-13 | ||
| US06/670,203 US4636564A (en) | 1984-11-13 | 1984-11-13 | 5-cyanopyridine-2-diazohydroxide, basic salts and methods for production and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61158967A JPS61158967A (ja) | 1986-07-18 |
| JPH0146511B2 true JPH0146511B2 (ja) | 1989-10-09 |
Family
ID=24689433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60253621A Granted JPS61158967A (ja) | 1984-11-13 | 1985-11-12 | ïŒâã·ã¢ãããªãžã³âïŒâãžã¢ãŸããããã·ãã®å¡©åºæ§å¡©ããã³ãã®è£œæ³ããã³äœ¿çšæ³ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4636564A (ja) |
| EP (1) | EP0181636B1 (ja) |
| JP (1) | JPS61158967A (ja) |
| AT (1) | ATE50566T1 (ja) |
| AU (1) | AU576914B2 (ja) |
| CA (1) | CA1255654A (ja) |
| DE (1) | DE3576154D1 (ja) |
| DK (1) | DK159847C (ja) |
| ES (1) | ES8700238A1 (ja) |
| ZA (1) | ZA858315B (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816468A (en) * | 1984-11-13 | 1989-03-28 | The University Of Alabama | 5-cyanopyridine-2-diazohydroxide, basic salts and use |
| DE4301109A1 (de) * | 1993-01-18 | 1994-07-21 | Bayer Ag | Verfahren zur Herstellung von 6-Amino-nicotinsÀurenitrilen |
| ITMI20011495A1 (it) * | 2001-07-12 | 2003-01-12 | Pharmaproducts Uk Ltd | Sali di calcio ad attivita' citotossica |
| CN107602456B (zh) * | 2017-10-19 | 2021-04-06 | å京å°å·åŠé¢ | å¶æ°®å¡å¶çååç©åå¶å€æ¹æ³ |
-
1984
- 1984-11-13 US US06/670,203 patent/US4636564A/en not_active Expired - Fee Related
-
1985
- 1985-10-29 ZA ZA858315A patent/ZA858315B/xx unknown
- 1985-11-07 DK DK514285A patent/DK159847C/da not_active IP Right Cessation
- 1985-11-12 ES ES548791A patent/ES8700238A1/es not_active Expired
- 1985-11-12 JP JP60253621A patent/JPS61158967A/ja active Granted
- 1985-11-13 CA CA000495196A patent/CA1255654A/en not_active Expired
- 1985-11-13 DE DE8585114440T patent/DE3576154D1/de not_active Expired - Lifetime
- 1985-11-13 AU AU49835/85A patent/AU576914B2/en not_active Ceased
- 1985-11-13 EP EP85114440A patent/EP0181636B1/en not_active Expired - Lifetime
- 1985-11-13 AT AT85114440T patent/ATE50566T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE50566T1 (de) | 1990-03-15 |
| ES548791A0 (es) | 1986-10-01 |
| US4636564A (en) | 1987-01-13 |
| JPS61158967A (ja) | 1986-07-18 |
| AU576914B2 (en) | 1988-09-08 |
| DK159847B (da) | 1990-12-17 |
| DK514285A (da) | 1986-05-14 |
| CA1255654A (en) | 1989-06-13 |
| DK159847C (da) | 1991-05-13 |
| EP0181636B1 (en) | 1990-02-28 |
| DK514285D0 (da) | 1985-11-07 |
| AU4983585A (en) | 1986-05-22 |
| DE3576154D1 (de) | 1990-04-05 |
| ES8700238A1 (es) | 1986-10-01 |
| ZA858315B (en) | 1986-10-29 |
| EP0181636A3 (en) | 1987-04-01 |
| EP0181636A2 (en) | 1986-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0043123B1 (en) | Novel substituted pyrazinyl-1,2,4-oxadiazol-5-ones, a process for preparing same and a pharmaceutical composition containing same | |
| KR100842400B1 (ko) | ê²°ì ì± êžë£šìœì¬ë¯Œ ì€íìŽíž êžììŒ ë° ê·žì ì ì¡°ë°©ë² | |
| US3709991A (en) | Hypolipidemic method | |
| JPH0146511B2 (ja) | ||
| JPH01216995A (ja) | çµæ¶åããã»ãã§ã âé žä»å å¡©ããã³ãããã®è£œæ³ | |
| US3923994A (en) | Anti-arthritic compositions comprising a 3-aryl 2-thiohydantoin and methods of producing anti-arthritic acitvity | |
| US3852292A (en) | 2-(pyridyl)-imidazole-4,5-dicarboxylic acid and derivatives | |
| CA2021042A1 (en) | Salts of n ,n -methylene-5,6,7,8-tetrahydrofolic acid | |
| US3822256A (en) | Crystalline monohydrates of sodium and potassium cephalexin | |
| US3903159A (en) | Methanesulfonamidophenyl guanidine compounds | |
| US4098892A (en) | Nicotinamido-s-triazines | |
| US3907767A (en) | 1-Phenyl-3-hydroxy-3-methyl-triazenes | |
| US4709033A (en) | Pyrazine diazohydroxide compounds and methods for their production and use | |
| US4816468A (en) | 5-cyanopyridine-2-diazohydroxide, basic salts and use | |
| US4235895A (en) | Substituted 5H-dibenz[b,f]azepine | |
| KR880001865B1 (ko) | 4-(1-ìŽë¯žë€ì¡žìŒë©íž)ì ëšì° íìŽëë¡íŽë¡ëŒìŽë ëªšë žíìŽëë ìŽížì ì ì¡°ë°©ë² | |
| US3714363A (en) | Substituted amino guanidine as anti-diabetic agents | |
| EP0335408A2 (en) | Substituted benzene derivatives, processes for their production and antitumour compositions containing them | |
| US6060498A (en) | Composition containing antitumor agent | |
| US3738990A (en) | Nicotinic acid derivatives | |
| US4845101A (en) | Pyrazine diazohydroxide compositions and method of use as cytostatic agent | |
| JPS6281365A (ja) | ã°ã¢ããžããšã¿ã³ããªã¹ã«ãã³é žããã®è£œé æ³ãåã³ãããå«æããã³ã¬ã¹ããâã«äœäžå€ | |
| US7019156B2 (en) | Tumor inhibiting gallium compounds | |
| US4218465A (en) | Glyoxylic acid hydrocarbylsulfonylhydrazones and therapeutic compositions | |
| US4287355A (en) | Carboxyl-(phenyl or tolyl)-sulfonium salts |